These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 1531693)

  • 1. Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer.
    Mason RP; Moisey DM; Shajenko L
    Mol Pharmacol; 1992 Feb; 41(2):315-21. PubMed ID: 1531693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes.
    Mason RP; Campbell SF; Wang SD; Herbette LG
    Mol Pharmacol; 1989 Oct; 36(4):634-40. PubMed ID: 2554114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.
    Huber I; Wappl E; Herzog A; Mitterdorfer J; Glossmann H; Langer T; Striessnig J
    Biochem J; 2000 May; 347 Pt 3(Pt 3):829-36. PubMed ID: 10769189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties.
    Herbette LG; Vecchiarelli M; Sartani A; Leonardi A
    Blood Press Suppl; 1998; 2():10-7. PubMed ID: 9850437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of the calcium antagonism of lacidipine by kinetic analysis.
    Giacometti A; Micheli D; Gaviraghi G; Trist DG
    J Pharmacol Exp Ther; 1994 Apr; 269(1):424-9. PubMed ID: 8169848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The unique binding properties of amlodipine: a long-acting calcium antagonist.
    Nayler WG; Gu XH
    J Hum Hypertens; 1991 Aug; 5 Suppl 1():55-9. PubMed ID: 1834847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Residual inhibition in density of [3H]isradipine binding sites in rat brain membrane pretreated with amlodipine.
    Qu YL; Takamizawa C; Sugiyama K; Maruyama K; Hattori K; Watanabe K; Nagatomo T
    Zhongguo Yao Li Xue Bao; 1995 Jul; 16(4):289-93. PubMed ID: 7668092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of inorganic calcium channel blockers on dihydropyridine binding to cardiac sarcolemma.
    Schilling WP; Zaher MC; Rampe D
    Mol Pharmacol; 1990 Jan; 37(1):80-9. PubMed ID: 2137194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine.
    Guarneri L; Angelico P; Ibba M; Poggesi E; Taddei C; Leonardi A; Testa R
    Arzneimittelforschung; 1996 Jan; 46(1):15-24. PubMed ID: 8821512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of calcium channel inhibition by phenytoin: comparison with classical calcium channel antagonists.
    Messing RO; Carpenter CL; Greenberg DA
    J Pharmacol Exp Ther; 1985 Nov; 235(2):407-11. PubMed ID: 2414431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse.
    Taylor JM; Simpson RU
    Cancer Res; 1992 May; 52(9):2413-8. PubMed ID: 1533173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of charged and uncharged calcium channel antagonists with phospholipid membranes. Binding equilibrium, binding enthalpy, and membrane location.
    Bäuerle HD; Seelig J
    Biochemistry; 1991 Jul; 30(29):7203-11. PubMed ID: 1830218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular and myocardial effects of amlodipine: an overview.
    Nayler WG; Gu XH
    Postgrad Med J; 1991; 67 Suppl 5():S41-3. PubMed ID: 1839439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes.
    Nokin P; Clinet M; Beaufort P; Meysmans L; Laruel R; Chatelain P
    J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for the inhibition of 1,4-dihydropyridine calcium channel drugs binding to their receptors by a nonspecific site interaction mechanism.
    Young HS; Skita V; Mason RP; Herbette LG
    Biophys J; 1992 May; 61(5):1244-55. PubMed ID: 1318093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subunit composition is a major determinant in high affinity binding of a Ca2+ channel blocker.
    Suh-Kim H; Wei X; Birnbaumer L
    Mol Pharmacol; 1996 Nov; 50(5):1330-7. PubMed ID: 8913365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-affinity antibodies to the 1,4-dihydropyridine Ca2+-channel blockers.
    Campbell KP; Sharp A; Strom M; Kahl SD
    Proc Natl Acad Sci U S A; 1986 May; 83(9):2792-6. PubMed ID: 3010317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels.
    Hagiwara M; Adachi-Akahane S; Nagao T
    J Pharmacol Exp Ther; 1997 Apr; 281(1):173-9. PubMed ID: 9103495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of binding of membrane-active drugs to receptor sites. Diffusion-limited rates for a membrane bilayer approach of 1,4-dihydropyridine calcium channel antagonists to their active site.
    Rhodes DG; Sarmiento JG; Herbette LG
    Mol Pharmacol; 1985 Jun; 27(6):612-23. PubMed ID: 2987659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacological profile of amlodipine in relation to ischaemic heart disease.
    Burges RA
    Postgrad Med J; 1991; 67 Suppl 3():S9-15. PubMed ID: 1836872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.